Nauck MA, McGuire DK, Pieper KS, et al. - In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), researchers focused on the influences of the sitagliptin (a dipeptidyl peptidase-4 inhibitor) on cardiovascular (CV) outcomes during and following incident myocardial infarction (MI) among people (n = 14,671) with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). The participants randomly received sitagliptin or placebo along with usual care. During TECOS, ≥ 1 MI was noted in 616 participants (sitagliptin group 300, placebo group 316), including 25 fatal [11 and 14, respectively]). Those with a nonfatal MI were 591 in total, of these, the subsequent death of 87 (15%) was reported, with 66 (11%) being CV deaths, and 57 (10%) had hospitalization for heart failure (hHF). As opposed to expectations derived from preclinical animal models, this study revealed no subsequent reduction in the risk of CV death or hHF in correlation with sitagliptin treatment in patients with type 2 diabetes and ASCVD experiencing an MI.